McKesson (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, a privately held provider of biomarker and clinical research services, the drugs distributor said on 25 August 2026.
The Precision Medicine Group acquisition is worth approximately $2.25bn, according to McKesson’s announcement.
Deal terms and strategic fit
Precision Medicine Group, based in Bethesda, Maryland, offers biomarker intelligence, laboratory services, a global contract research organisation, market access consulting and commercialisation support, Reuters reported.
Once the deal closes, the business will report within McKesson’s Oncology & Multispecialty segment, the company said. Brian Tyler, McKesson’s chair and chief executive, called the transaction ‘another meaningful step in advancing our oncology and multispecialty strategy’.
The transaction is subject to customary closing conditions, including regulatory clearances. Neither company has disclosed a target closing date.
Shares climb as segment growth accelerates
MCK shares closed at $905.09 on the day of the announcement, up 3.0% on the session and 6.26% over the prior 20 trading days, according to consolidated exchange data. The stock touched a 20-day high of $905.65, just above the closing print.
The acquisition lands in a segment already expanding fast. McKesson’s Oncology & Multispecialty unit, the one Precision Medicine Group will join, posted a 33% revenue increase to $14.2bn in the most recent quarter, Quartz reported, giving context for why McKesson is doubling down on the business line rather than distribution.
A wider portfolio shift
The purchase follows other recent moves reshaping McKesson’s portfolio. The company has also agreed to divest a minority stake in its medical-surgical solutions unit to Apollo Funds for $1.25bn, ahead of a planned initial public offering, Quartz reported. Taken together, the two transactions point to a group rotating capital away from legacy pill distribution and toward specialty data and services businesses such as biomarker testing and contract research.
McKesson’s underlying financial base for that pivot has been steady. In its fiscal first quarter of 2027, the three months to 30 June 2026, the company reported consolidated revenue of $105.38bn and diluted earnings per share of $5.15, according to a filing with the US Securities and Exchange Commission. That followed a run of quarters in which revenue climbed steadily: from $95.29bn in the quarter to December 2024 to $103.15bn in the quarter to September 2025 and $106.16bn in the quarter to December 2025, EDGAR filings show. Diluted EPS over the same run swung between $1.87 and $9.59 a share, reflecting the seasonal pattern typical of McKesson’s distribution-heavy revenue base.
Financing backdrop
McKesson is pursuing the deal against a Treasury market that has been broadly stable. The 10-year US Treasury yield stood at 4.70% on 24 August 2026, little changed from 4.74% a week earlier, according to Federal Reserve data. The 2-year yield held at 4.24%, leaving the 10-year/2-year spread at 0.47 percentage points, close to its recent range. That relative calm in borrowing costs offers a steadier backdrop for financing a multibillion-dollar cash acquisition than markets have seen in some of the more volatile stretches of the past two years.
Trading activity around the announcement showed some divergence from the share-price move. FINRA short-sale volume data put MCK’s short-volume ratio at 0.699 on 25 August, up sharply from 0.436 on 12 August and above every reading in the preceding fortnight, even as the stock advanced on the day. Elevated short-side activity alongside a rising share price does not, on its own, indicate a change in sentiment, but it is a detail traders tracking the stock into the deal’s closing will likely watch alongside any regulatory filings on the transaction.
No closing date has been set. Market participants will be watching for antitrust clearance filings and for McKesson’s next quarterly results, due in the autumn, for any update on integration plans for the Oncology & Multispecialty segment.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
